Audentes Therapeutics, Inc. a biotechnology company, is engaged in the development and commercialization of new gene therapy treatments for people with serious rare diseases. It is engaged in the development of AT001 for the treatment of X-linked myotubular myopathy; AT002 for the treatment of pompe disease; and AT003 for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. was founded in 2012 and is based in San Francisco, California.
101 Montgomery Street
San Francisco, CA 94104
Founded in 2012
Audentes Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM
Oct 2 15
Audentes Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 01:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Genine Winslow, Director of Research Analytics.
Audentes Therapeutics, Inc. Announces Management Appointments
Sep 29 15
Audentes Therapeutics, Inc. announced the addition of three accomplished biopharmaceutical executives to its leadership team. Natalie Holles has joined Audentes as Senior Vice President and Chief Operating Officer, Thomas Soloway has joined as Senior Vice President and Chief Financial Officer and Kevin Baker, Ph.D. has joined as Senior Vice President, Preclinical Development. In these newly created roles, each will report to Matthew Patterson, President and Chief Executive Officer of Audentes Therapeutics, Inc. Ms. Holles joins Audentes with over 15 years of corporate development, strategic planning, and commercial experience, gained in a range of therapeutic areas and with a focus on orphan diseases. Most recently, Ms. Holles served as Senior Vice President, Corporate Development at Hyperion Therapeutics, Inc. from 2013 through its acquisition by Horizon Pharma, plc in May 2015. From 2010-2013, Ms. Holles provided executive-level strategy and business development advisory services to a number of privately-held biopharmaceutical companies, most recently acting as Executive Vice President, Corporate Development at Immune Design, Inc. Earlier in her career, Ms. Holles served as Vice President, Business Development at KAI Pharmaceuticals, Inc. (acquired by Amgen in 2012) and previously held corporate development and commercial roles at InterMune, Inc. (acquired by Roche in 2014) and Genentech, Inc. Mr. Soloway joins Audentes with over 20 years of experience in operations, corporate finance, and venture capital related to the life sciences industry. Prior to joining Audentes, Mr. Soloway served as the Senior Vice President, Chief Financial Officer of Ascendis Pharma A/S, a Danish biopharmaceutical company, where he helped lead a successful initial public offering on NASDAQ. Prior to Ascendis, Mr. Soloway co-founded Transcept Pharmaceuticals, Inc. Dr. Baker joins Audentes with over 20 years of experience in the discovery and development of novel biologic drugs for a wide range of diseases. Dr. Baker most recently served as Vice President, Preclinical Development at FivePrime Therapeutics, Inc.
Audentes Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:50 AM
Sep 25 15
Audentes Therapeutics, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 08:50 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Matthew R. Patterson, Chief Executive Officer, President and Director.